VTVT | tickerfilter.com

Fundamental analysis

33%

Profitability 36%

Dept financing 50%

Liquidity 15%

Performance 29%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-6.46%

1 Month

-3.68%

3 Months

-33.91%

6 Months

-5.65%

1 Year

-21.61%

2 Year

-61.87%

Key data

Stock price

$16.16

P/E Ratio

0.00

DAY RANGE

N/A - N/A

EPS

$0.00

52 WEEK RANGE

$7.38 - $30.99

52 WEEK CHANGE

-$0.23

MARKET CAP

38.220 M

YIELD

N/A

SHARES OUTSTANDING

2.433 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$36,398

AVERAGE 30 VOLUME

$38,117

Company detail

CEO: Stephen Holcombe
Region: US
Website: http://vtvtherapeutics.com/
Employees: 55
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

vtv therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. we have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, diabetes and metabolic disorders, inflammation and cancer.

VTVT - vTv Therapeutics Inc - Ordinary Shares - Class A